Stockscreener 앱 받기
1.59
3.05%
-0.05
전일 마감가:
$1.64
열려 있는:
$1.65
하루 거래량:
68,275
Relative Volume:
0.30
시가총액:
$30.92M
수익:
-
순이익/손실:
$-33.08M
주가수익비율:
-0.5408
EPS:
-2.94
순현금흐름:
$-25.68M
1주 성능:
-8.62%
1개월 성능:
-2.45%
6개월 성능:
+93.90%
1년 성능:
+218.64%
1일 변동 폭
$1.55
$1.68
1주일 범위
$1.54
$1.79
52주 변동 폭
$0.42
$2.55
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
명칭
Chemomab Therapeutics Ltd Adr
전화
972-77-331-0156
주소
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
CMMB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CMMB | 1.59 | 30.92M | 0 | -33.08M | -25.68M | -2.94 |
| VRTX | 448.89 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.63 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.08 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.44 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Chemomab Therapeutics Ltd Adr 주식(CMMB)의 최신 뉴스
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.
Chemomab reports progress in PSC treatment trial - Investing.com
Roth MKM Initiates Coverage of Chemomab Therapeutics LtdADR (CMMB) with Buy Recommendation - MSN
The Chemomab Therapeutics Ltd ADR (CMMB) had a good session last reading, didn’t it? - US Post News
Financial Health Check: Examining Chemomab Therapeutics Ltd ADR (CMMB)’s Key Ratios - The Dwinnex
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ratios Uncovered: Breaking Down Chemomab Therapeutics Ltd ADR (CMMB)’s Trailing Twelve Months Metrics - The Dwinnex
Is Chemomab Therapeutics Ltd ADR (CMMB) a good investment opportunity? - US Post News
CMMB stock touches 52-week high at $2.07 amid market fluctuations - Investing.com
Chemomab Therapeutics Ltd ADR (CMMB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Are Chemomab Therapeutics Ltd ADR (CMMB) shares a good deal now? - US Post News
CMMB stock touches 52-week high at $1.58 amid market fluctuations - Investing.com India
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Market Analysts see American Express Co. [AXP] gaining to $265. Time to buy? - The DBT News
Chemomab Therapeutics Ltd ADR [CMMB] moved down -16.20: Why It’s Important - The DBT News
Chemomab regains Nasdaq compliance with bid price rule - Investing.com
Public Service Enterprise Group Inc. [PEG] Revenue clocked in at $9.72 billion, up 21.41% YTD: What’s Next? - The DBT News
Cerevel Therapeutics Holdings Inc [CERE] Is Currently 2.37 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Ardelyx Inc [ARDX] moved down -2.31: Why It’s Important - The DBT News
CMMB’s 2023 Market Dance: Up 107.84% – Time to Invest? - The InvestChronicle
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise - Benzinga
Chemomab secures $10 million in PIPE financing - Investing.com India
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Yahoo News Malaysia
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - MSN
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - Investing.com India
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update - Investing.com India
LGVN Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Why Copart, Inc. (CPRT) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire
Chemomab Stock: Leading Anti-CCL24 mAb For Fibrotic Diseases (NASDAQ:CMMB) - Seeking Alpha
Chemomab And AGC Biologics Partner To Manufacture CM-101 For Phase II/III - Contract Pharma
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
Chemomab Therapeutics (NASDAQ:CMMB) Stock Quotes, Forecast and News Summary - Benzinga
The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal - Yahoo Finance
Chemomab Therapeutics Ltd Adr (CMMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):